JP2018503685A5 - - Google Patents

Download PDF

Info

Publication number
JP2018503685A5
JP2018503685A5 JP2017556784A JP2017556784A JP2018503685A5 JP 2018503685 A5 JP2018503685 A5 JP 2018503685A5 JP 2017556784 A JP2017556784 A JP 2017556784A JP 2017556784 A JP2017556784 A JP 2017556784A JP 2018503685 A5 JP2018503685 A5 JP 2018503685A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
net
inhibitor
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017556784A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018503685A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/013847 external-priority patent/WO2016118476A1/en
Publication of JP2018503685A publication Critical patent/JP2018503685A/ja
Publication of JP2018503685A5 publication Critical patent/JP2018503685A5/ja
Pending legal-status Critical Current

Links

JP2017556784A 2015-01-20 2016-01-19 線維化を処置および予防するためのならびに創傷治癒を促進するための抗ｎｅｔ化合物 Pending JP2018503685A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562105342P 2015-01-20 2015-01-20
US62/105,342 2015-01-20
PCT/US2016/013847 WO2016118476A1 (en) 2015-01-20 2016-01-19 Anti-net compounds for treating and preventing fibrosis and for facilitating wound healing

Publications (2)

Publication Number Publication Date
JP2018503685A JP2018503685A (ja) 2018-02-08
JP2018503685A5 true JP2018503685A5 (enExample) 2019-02-21

Family

ID=56417634

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017556784A Pending JP2018503685A (ja) 2015-01-20 2016-01-19 線維化を処置および予防するためのならびに創傷治癒を促進するための抗ｎｅｔ化合物

Country Status (5)

Country Link
US (3) US11400139B2 (enExample)
EP (2) EP3247386A4 (enExample)
JP (1) JP2018503685A (enExample)
CA (1) CA2974369A1 (enExample)
WO (1) WO2016118476A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3351263A1 (en) * 2017-01-20 2018-07-25 Universitätsklinikum Hamburg-Eppendorf Pharmaceutical preparation for treating or preventing tissue adhesion
AU2018318313B2 (en) 2017-08-18 2025-01-23 Neutrolis Inc. Engineered DNase enzymes and use in therapy
WO2019173835A1 (en) * 2018-03-09 2019-09-12 The University Of Memphis Research Foundation Compositions and methods for inhibiting inflammation
WO2020006389A1 (en) * 2018-06-29 2020-01-02 Viktor Veniaminovich Tets Compositions for modulating gut microbiota
CN114341111B (zh) * 2019-09-06 2024-11-29 阿根廷国家科学技术研究委员会 用于局部伤口治疗的药物组合物
GB202012326D0 (en) * 2020-08-07 2020-09-23 Citryll B V Diagnostic
CN113358872B (zh) * 2021-06-03 2022-10-21 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 用于评估肿瘤免疫治疗疗效的标志物组及系统

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3270960A (en) 1964-09-11 1966-09-06 Sperry Rand Corp Fluid sensor
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4534899A (en) 1981-07-20 1985-08-13 Lipid Specialties, Inc. Synthetic phospholipid compounds
US4426330A (en) 1981-07-20 1984-01-17 Lipid Specialties, Inc. Synthetic phospholipid compounds
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4920016A (en) 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
US6919320B1 (en) * 1987-10-28 2005-07-19 Wellstat Therapeutics Corporation Pharmaceutical compositions containing deoxyribonucleosides for wound healing
GB8824593D0 (en) 1988-10-20 1988-11-23 Royal Free Hosp School Med Liposomes
DE68929551T2 (de) 1988-12-23 2008-03-06 Genentech, Inc., South San Francisco Menschliche DNase
DE3903672C1 (enExample) 1989-02-08 1990-02-01 Lohmann Gmbh & Co Kg
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5356633A (en) 1989-10-20 1994-10-18 Liposome Technology, Inc. Method of treatment of inflamed tissues
US5665710A (en) 1990-04-30 1997-09-09 Georgetown University Method of making liposomal oligodeoxynucleotide compositions
JP3220180B2 (ja) 1991-05-23 2001-10-22 三菱化学株式会社 薬剤含有タンパク質結合リポソーム
JP3351476B2 (ja) 1993-01-22 2002-11-25 三菱化学株式会社 リン脂質誘導体及びそれを含有するリポソーム
US5395619A (en) 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
US6191105B1 (en) 1993-05-10 2001-02-20 Protein Delivery, Inc. Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
CA2137297C (en) 1993-12-06 2000-04-18 Tsuyoshi Miyazaki Reactive vesicle and functional substance-fixed vesicle
US5543152A (en) 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5820873A (en) 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
US5756122A (en) 1995-06-07 1998-05-26 Georgetown University Liposomally encapsulated nucleic acids having high entrapment efficiencies, method of manufacturer and use thereof for transfection of targeted cells
US5539878A (en) 1995-06-16 1996-07-23 Elonex Technologies, Inc. Parallel testing of CPU cache and instruction units
US5858397A (en) 1995-10-11 1999-01-12 University Of British Columbia Liposomal formulations of mitoxantrone
US5858401A (en) 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
EP1012331B1 (en) 1997-07-01 2006-03-29 Isis Pharmaceuticals, Inc. Compositions and methods for the delivery of oligonucleotides via the alimentary canal
JP2002537343A (ja) 1999-02-23 2002-11-05 アイシス・ファーマシューティカルス・インコーポレーテッド 多重粒子製剤
IT1318539B1 (it) 2000-05-26 2003-08-27 Italfarmaco Spa Composizioni farmaceutiche a rilascio prolungato per lasomministrazione parenterale di sostanze idrofile biologicamente
WO2003015698A2 (en) 2001-08-13 2003-02-27 University Of Pittsburgh Application of lipid vehicles and use for drug delivery
JPWO2005075414A1 (ja) 2004-02-04 2007-10-11 公立大学法人横浜市立大学 ペプチジルアルギニンデイミナーゼ４阻害剤
US20070213292A1 (en) 2005-08-10 2007-09-13 The Rockefeller University Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
WO2007056389A2 (en) 2005-11-07 2007-05-18 University Of South Carolina Synthesis and use of novel inhibitors and inactivators of protein arginine deiminases
US8617542B2 (en) 2008-04-03 2013-12-31 Kane Biotech Inc. DispersinB™, 5-fluorouracil, deoxyribonuclease I and proteinase K-based antibiofilm compositions and uses thereof
EP2288616B1 (en) 2008-06-16 2012-11-21 Chiralix B.V. Peptidylarginine deiminase (pad) inhibitors
US9642822B2 (en) * 2011-05-27 2017-05-09 Children's Medical Center Corporation Methods for treating and preventing neutrophil-derived net toxicity and thrombosis
EP2775304A1 (en) * 2013-03-07 2014-09-10 Universitätsspital Basel Methods for detecting inflammatory disorder
JP6327626B2 (ja) * 2013-04-09 2018-05-23 国立大学法人 東京大学 白血球の細胞外トラップ形成の阻害剤
GB201309180D0 (en) 2013-05-21 2013-07-03 Ucl Business Plc Compounds and Their Uses
CN105358187B (zh) * 2013-06-24 2018-06-22 登士伯Ih有限公司 包含胶原-vi的医疗装置

Similar Documents

Publication Publication Date Title
JP2018503685A5 (enExample)
Neckers et al. Methods to validate Hsp90 inhibitor specificity, to identify off-target effects, and to rethink approaches for further clinical development
EP4230623A3 (en) Pyridine compounds as allosteric shp2 inhibitors
CN111868056A (zh) 1,2,4-噁二唑类化合物及其制备方法和医药用途
CL2011000867A1 (es) Formas cristalinas da, c y ii de (r)-5-[3-cloro-4-(2,3-dihidroxi-propoxi)- benz[z]ilideno]-2- ([z]- propilimino) -3-o- totil-tiazolidin-4-ona; composicion farmaceutica; y uso en el tratamiento o prevencion de rechazo de organos trasplantados, sindrome autoinmunitarios, asma, diabetes, cancer.
JP2007523049A5 (enExample)
WO2006014353A3 (en) Glycogen or polysaccharide storage disease treatment method
WO2006037031A3 (en) Formulations and methods for treatment of inflammatory diseases
RU2018121036A (ru) Комбинированная пре- и пробиотическая композиция
WO2011116026A3 (en) Inhibitors of beta integrin-g protein alpha subunit binding interactions
WO2015095834A3 (en) Cancer treatments using erk1/2 and bcl-2 family inhibitors
JP2019500056A5 (enExample)
WO2009004995A1 (ja) 生理活性物質を定着および発現させる方法
EP4410833A3 (en) Compositions and methods for treating fatty tissue buildup
Garrido et al. Medical course and complications after lung transplantation
MX2021000340A (es) Nuevos compuestos.
JP2017536380A5 (enExample)
CN110546150A (zh) 含吡唑基的三并环类衍生物、其制备方法和应用
JP2019533715A5 (enExample)
Jørgensen et al. Isotretinoin and hidradenitis suppurativa
JP2020523375A5 (enExample)
MX2024003859A (es) Inhibidores de lpxc y usos de estos.
WO2020060779A3 (en) Methods and compositions for treating laminopathies affecting skeletal or cardiac muscle
JP2018536620A5 (enExample)
Chen et al. New options for pneumothorax management